Tian W et al. reported that patients with acquired lymphedema have elevated levels of the proinflammatory mediator leukotriene B4 (LTB4), which inhibits VEGFR3 and Notch signaling involved in lymphedema. This evidence concerns the gene FLT4 and lymphedema.